Psilocybin Executive Order: Trump Fast-Tracks FDA Approval — What It Means for Ann Arbor

Breaking news, April 18, 2026: President Trump signed a psilocybin executive order titled “Accelerating Medical Treatments for Serious Mental Illness” — directing the FDA to fast-track review of psilocybin and ibogaine, allocating $50 million in federal funding for psychedelic research, and opening a legal pathway for eligible patients to access these substances under the Right to Try Act.

This psilocybin executive order is the most significant federal policy shift on psychedelics in decades. For a community like Ann Arbor — which decriminalized psilocybin back in 2020 — today’s news feels less like a surprise and more like the rest of the country finally catching up.

Here’s everything you need to know: what the psilocybin executive order actually does, what it means for FDA approval, where states already stand, and what it means practically for you.

What the Psilocybin Executive Order Actually Does

The executive order has six operative sections. Here’s a plain-language breakdown of the most important provisions:

FDA Fast-Track Vouchers for Psychedelic Compounds

FDA Commissioner Mary Makary will issue Commissioner’s National Priority Vouchers to qualifying psychedelic drugs that already hold FDA Breakthrough Therapy designation. These vouchers accelerate the review timeline — Makary has stated that expedited approval could come within weeks, not years. According to NPR, next week the FDA will issue national priority vouchers for three specific psychedelic compounds. This is the first time in history the FDA has fast-tracked any psychedelic substance.

Right to Try Pathway for Patients

The order directs the FDA and DEA to establish a formal pathway for eligible patients to access psychedelic drugs — including ibogaine — under the Right to Try Act. This includes Schedule I handling authorizations for qualifying physicians and researchers. In practical terms, seriously ill patients who have exhausted other options may be able to access these treatments before full FDA approval is granted. This provision of the psilocybin executive order could have an immediate impact for qualifying patients.

$50 Million in Federal Funding via ARPA-H

The Department of Health and Human Services (HHS), through the Advanced Research Projects Agency for Health (ARPA-H), is directed to allocate at least $50 million from existing funds to support state governments that are already developing or running psychedelic therapy programs. This includes federal funding, technical assistance, and data sharing with states like Oregon, Colorado, Connecticut, and Minnesota.

Psilocybin Executive Order: Rescheduling Review

Section 5 of the order directs the Attorney General — in consultation with HHS — to initiate and complete a review of Schedule I substances that have completed Phase 3 clinical trials for serious mental health disorders, with the goal of rescheduling them “as quickly as practicable” following FDA approval. Both psilocybin and ibogaine are currently Schedule I under the Controlled Substances Act.

VA Clinical Trial Expansion

The Department of Veterans Affairs is currently engaged in at least five clinical trials across New York, California, and Oregon studying psychedelics for PTSD treatment. The psilocybin executive order directs HHS and FDA to collaborate with the VA to increase clinical trial participation and enable data sharing to speed up formal evaluation.

The order was signed in the Oval Office. Attendees included HHS Secretary RFK Jr., Dr. Mehmet Oz (Centers for Medicare and Medicaid Services), Navy SEAL and Lone Survivor author Marcus Luttrell, and podcast host Joe Rogan. Luttrell, speaking of his personal experience with ibogaine therapy, said: “It absolutely changed my life for the better.” Rogan shared that he messaged Trump about ibogaine and received the reply: “Great. You want approval? Let’s do it.” Trump himself quipped to the room: “Can I have some, please?”

What the Psilocybin Executive Order Means for FDA Approval

FDA Breakthrough Designations Already in Place

Before today’s psilocybin executive order, the FDA had already granted Breakthrough Therapy designation to multiple psychedelic compounds. According to a January 2026 review published in Nature, those designations include psilocybin for treatment-resistant depression (TRD), LSD for generalized anxiety disorder (GAD), and MDMA for PTSD. The executive order builds on top of this existing infrastructure — it doesn’t create new scientific findings, it accelerates what was already in the pipeline.

Compass Pathways and the 2026 Timeline

Compass Pathways, one of the leading clinical-stage psychedelic companies, reported in February 2026 that psilocybin treatment trials showed a “generally well-tolerated and safe profile.” The company expects an FDA decision on psilocybin for severe depression by the end of 2026. Today’s psilocybin executive order makes that timeline significantly more plausible.

A Sharp Reversal from 2024

In 2024, the FDA denied approval for MDMA as a PTSD treatment — a decision widely seen as a signal of the agency’s caution around psychedelics. Today’s order represents a clear policy reversal. The emphasis has shifted from “wait and see” to “accelerate with appropriate safeguards.” The inclusion of Right to Try pathways is especially significant: it means some patients won’t have to wait for full approval at all.

Why Psilocybin’s Potential Matters

The mental health need is real and significant. The National Institute of Mental Health reports that over 21 million American adults experienced at least one major depressive episode, and approximately 1 in 10 Americans has been diagnosed with Generalized Anxiety Disorder. A 2025 study published in the Journal of the American Medical Association found that a single dose of LSD alleviated anxiety and depression for several months. Psilocybin research has shown similarly durable effects in multiple peer-reviewed trials, which is part of why it received Breakthrough Therapy designation in the first place.

The Bigger Picture: States Were Already Moving Before the Psilocybin Executive Order

Federal action is catching up to a wave that began at the state level. As High Times reported on April 17, 2026, more psychedelic legislation is advancing simultaneously across the country than at any other point in history. Here’s where things stand:

Public opinion has tracked alongside legislation. According to a 2023 survey from UC Berkeley, 3 in 5 Americans support legalizing regulated therapeutic access to psychedelics. The psilocybin executive order reflects that shifting consensus — and gives federal backing to what states have been building on their own. For a broader overview of where psychedelic legalization stands nationwide, see this GoodRx overview of psychedelic legalization by state.

Why Ann Arbor Was Already Ahead of the Psilocybin Executive Order

Ann Arbor didn’t wait for Washington. In September 2020, the Ann Arbor City Council passed Resolution R-20-362 with a unanimous 11–0 vote, effectively decriminalizing psilocybin mushrooms and other entheogenic plants. The following year, Washtenaw County Prosecutor Policy Directive 2021-06 reinforced non-prosecution of personal possession, giving residents and local businesses additional legal clarity.

That early, community-driven action created the conditions for a legitimate, accessible local market to develop — years before today’s federal news. Ann Arbor is not playing catch-up. It has been a national leader in this space, and the psilocybin executive order confirms the federal government is now moving in the same direction.

For a full breakdown of exactly what is and isn’t legal in Ann Arbor and Michigan right now, read our comprehensive guide: Psilocybin Legality in Ann Arbor — What You Need to Know.

What the Psilocybin Executive Order Means for You

Federal executive orders move fast but regulatory processes still take time. Here’s a realistic look at what today’s news means in practical terms:

If You’re in Ann Arbor

Today’s order does not change anything about local access in Ann Arbor. Psilocybin mushrooms remain decriminalized here under Resolution R-20-362, and Mush Love MI continues to operate openly and legally under that local framework. You don’t need to wait for federal approval — if you’re 21 or older, you can visit us today.

If You’re Curious About Microdosing

Interest in microdosing — the practice of taking small, sub-perceptual doses of psilocybin to support mood, focus, and well-being — has been growing alongside the research. Our complete guide to microdosing psilocybin covers protocols, dosing, and what to expect. We carry our CAPS LOCK microdose capsules at precisely 0.25g each — a reliable, consistent format for anyone exploring a structured microdose routine.

If You’re New to This

Federal momentum is bringing a lot of new people to the topic for the first time. If you’re curious but don’t know where to start, we’ve published a full library of guides: what to expect on your first visit, how to take magic mushrooms responsibly, and safety practices we recommend. Our complete guides page is a good home base.

If You’re Following the Policy Closely

Watch for FDA announcements next week when the agency is expected to issue national priority vouchers for three psychedelic compounds. The Compass Pathways FDA decision on psilocybin for severe depression is expected by end of 2026. Rescheduling of psilocybin and ibogaine is on the table — but contingent on FDA approval completing first. We’ll continue updating this blog as things develop.

The Research Is Promising — But Read It Carefully

Psilocybin is not a cure-all, and responsible reporting means acknowledging that. Most of the strongest evidence comes from controlled clinical settings with trained facilitators. Peer-reviewed research is genuinely promising — and the psilocybin executive order reflects growing government confidence in that research — but protocols matter. If you’re considering psilocybin for a specific health concern, we always encourage you to read the research, consult a medical professional, and come talk to us about what you’re looking for. Browse our strain guide and shop to understand the options available to you locally right now.

Frequently Asked Questions About the Psilocybin Executive Order

Is psilocybin legal in Ann Arbor right now?

Psilocybin mushrooms are decriminalized in Ann Arbor under Resolution R-20-362, passed unanimously in September 2020. Washtenaw County Prosecutor Policy Directive 2021-06 further reinforced non-prosecution. Psilocybin remains a Schedule I substance under federal law, but today’s psilocybin executive order initiates a process toward rescheduling. For full details, see our Ann Arbor psilocybin legality guide.

What did the psilocybin executive order actually do?

The executive order directs the FDA to fast-track review of psilocybin and ibogaine through priority vouchers, opens a Right to Try pathway for eligible patients, allocates $50 million via ARPA-H for state psychedelic programs, and instructs the Attorney General to initiate rescheduling review for substances that complete Phase 3 trials. It does not immediately change the legal status of psilocybin — but it sets the regulatory machinery in motion.

When could psilocybin actually be FDA approved?

FDA Commissioner Mary Makary stated that expedited approval could come within weeks for qualifying compounds. Compass Pathways expects a specific FDA decision on psilocybin for severe depression by the end of 2026. Priority vouchers are expected to be issued next week for three psychedelic compounds. Full approval and rescheduling would follow a formal review process. As NPR reported, this is the first time the FDA has fast-tracked any psychedelic substance.

What is ibogaine and why is it in the executive order?

Ibogaine is a naturally occurring psychoactive compound derived from the West African iboga plant. It has shown significant potential for treating opioid dependency and PTSD, and has been used in clinical settings internationally for decades. Like psilocybin, it is currently Schedule I in the United States. The executive order specifically names ibogaine alongside psilocybin as a priority substance for accelerated FDA review and Right to Try access.

What is the Right to Try Act and how does it apply here?

The Right to Try Act (21 U.S.C. 360bbb-0a) allows terminally ill and seriously ill patients who have exhausted other options to access experimental treatments not yet fully approved by the FDA. The psilocybin executive order directs the FDA and DEA to establish a formal pathway for eligible patients to access psychedelic drugs — including Schedule I substances like psilocybin and ibogaine — through this act, including handling authorizations for qualifying physicians.

Does the psilocybin executive order affect me if I’m in Michigan?

Not immediately in terms of day-to-day access — Ann Arbor residents already have decriminalized access to psilocybin mushrooms. What the order does is signal federal momentum that could eventually lead to rescheduling, which would affect what healthcare providers can prescribe and how research funding flows. Michigan has not yet passed state-level therapeutic psilocybin legislation, but federal momentum and neighboring state action (Connecticut, Minnesota, New Jersey) are building pressure for that to change.

Is there scientific evidence supporting psilocybin for mental health?

Yes, and it’s growing. The FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression, LSD for generalized anxiety disorder, and MDMA for PTSD — a designation reserved for drugs showing substantial improvement over existing treatments, according to a January 2026 review in Nature. A 2025 study in JAMA found a single dose of LSD alleviated anxiety and depression for several months. Compass Pathways’ February 2026 data showed psilocybin to have a “generally well-tolerated and safe profile” in trials. The National Institute of Mental Health reports over 21 million American adults experienced a major depressive episode, underscoring why researchers are pursuing new treatment options.

What products does Mush Love MI carry?

We carry a wide range of products including dried mushrooms, microdose capsules at 0.25g each, mushroom chocolates, mushroom gummies, mushroom drinks, and a selection of functional mushrooms. Browse our full online shop or come in and talk to us. We’re walk-in friendly, 21+ with valid ID, and open 7 days a week.

Visit Mush Love MI

Ann Arbor has been ahead of this moment for years — and we’ve been here to serve this community the whole time. Whether you’re a longtime customer, someone newly curious after today’s psilocybin executive order headlines, or a researcher wanting to understand the local landscape, you’re welcome here.

Mush Love MI
2007 S State St, Ann Arbor, MI 48104
Phone: (734) 929-4207

Hours:
Sunday–Tuesday: 10am–8pm
Wednesday–Saturday: 10am–9pm

Good to know before you visit:

• 21+ with valid ID required
• Cash only — ATM on site
• Free parking available
• Walk-ins welcome — no appointment needed

Over 535+ five-star Google reviews from customers across Washtenaw County and beyond.

Ready to learn more before you visit? Start with our complete guides library, check out our strain guide, or browse the full shop. If you’re just getting started, our first visit guide walks you through exactly what to expect.

This is a significant moment for mental health, for psychedelic research, and for communities like ours that have been doing the quiet, principled work of building something better for years. We’re glad you’re here.